Ascletis Pharma Inc. (ASCLF)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
At close: 11:07AM EDT
| Previous Close | 0.2023 |
| Open | 0.2023 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's Range | 0.2023 - 0.2023 |
| 52 Week Range | 0.1547 - 0.3779 |
| Volume | |
| Avg. Volume | 265 |
| Market Cap | 204.881M |
| Beta (5Y Monthly) | 0.63 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.0200 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
PR NewswireAscletis Announces Strategic Decisions on FXR agonist ASC42
Ascletis Pharma Inc. (HKEX:1672, "Ascletis") announces today the strategic decisions on farnesoid X receptor (FXR) agonist ASC42.
PR NewswireAscletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces the poster presentation of Phase II study final results of ASC40, a first-in-class fatty acid synthase (FASN) inhibitor for treatment of acne, at the 2024 American Academy of Dermatology (AAD) Annual Meeting in San Diego, the United States.
PR NewswireAscletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announces dosing of the first patient in Phase III clinical trial of ASC40 (Denifanstat) for treatment of moderate to severe acne vulgaris at Huashan Hospital, Fudan University.
© 2024 Yahoo. All rights reserved.